chr12-63781033-G-A
Variant summary
Our verdict is Likely benign. Variant got -3 ACMG points: 2P and 5B. PM2BP4_StrongBS1_Supporting
The NM_014254.3(RXYLT1):c.184G>A(p.Glu62Lys) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000282 in 1,598,180 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 13/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_014254.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -3 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
RXYLT1 | NM_014254.3 | c.184G>A | p.Glu62Lys | missense_variant | 2/6 | ENST00000261234.11 | NP_055069.1 | |
RXYLT1 | XM_047428079.1 | c.184G>A | p.Glu62Lys | missense_variant | 2/5 | XP_047284035.1 | ||
RXYLT1 | NM_001278237.2 | c.-597G>A | 5_prime_UTR_variant | 2/6 | NP_001265166.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
RXYLT1 | ENST00000261234.11 | c.184G>A | p.Glu62Lys | missense_variant | 2/6 | 1 | NM_014254.3 | ENSP00000261234 | P1 | |
ENST00000509615.2 | n.238+14448C>T | intron_variant, non_coding_transcript_variant | 5 |
Frequencies
GnomAD3 genomes AF: 0.0000986 AC: 15AN: 152060Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.0000669 AC: 16AN: 238988Hom.: 0 AF XY: 0.0000695 AC XY: 9AN XY: 129528
GnomAD4 exome AF: 0.0000207 AC: 30AN: 1446002Hom.: 0 Cov.: 30 AF XY: 0.0000236 AC XY: 17AN XY: 719114
GnomAD4 genome AF: 0.0000986 AC: 15AN: 152178Hom.: 0 Cov.: 33 AF XY: 0.000121 AC XY: 9AN XY: 74394
ClinVar
Submissions by phenotype
not provided Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Sep 14, 2022 | In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge - |
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Aug 10, 2022 | This sequence change replaces glutamic acid, which is acidic and polar, with lysine, which is basic and polar, at codon 62 of the RXYLT1 protein (p.Glu62Lys). This variant is present in population databases (rs200250516, gnomAD 0.05%). This variant has not been reported in the literature in individuals affected with RXYLT1-related conditions. ClinVar contains an entry for this variant (Variation ID: 473413). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Inborn genetic diseases Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Aug 19, 2021 | The c.184G>A (p.E62K) alteration is located in exon 2 (coding exon 2) of the TMEM5 gene. This alteration results from a G to A substitution at nucleotide position 184, causing the glutamic acid (E) at amino acid position 62 to be replaced by a lysine (K). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at